216 related articles for article (PubMed ID: 18554581)
1. Association between acetylcholinesterase and beta-amyloid peptide in Alzheimer's cerebrospinal fluid.
García-Ayllón MS; Silveyra MX; Sáez-Valero J
Chem Biol Interact; 2008 Sep; 175(1-3):209-15. PubMed ID: 18554581
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with Alzheimer's disease.
García-Ayllón MS; Silveyra MX; Andreasen N; Brimijoin S; Blennow K; Sáez-Valero J
J Neurochem; 2007 Jun; 101(6):1701-11. PubMed ID: 17326766
[TBL] [Abstract][Full Text] [Related]
3. Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease.
Sáez-Valero J; Fodero LR; Sjögren M; Andreasen N; Amici S; Gallai V; Vanderstichele H; Vanmechelen E; Parnetti L; Blennow K; Small DH
J Neurosci Res; 2003 May; 72(4):520-6. PubMed ID: 12704813
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Parnetti L; Amici S; Lanari A; Romani C; Antognelli C; Andreasen N; Minthon L; Davidsson P; Pottel H; Blennow K; Gallai V
Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
[TBL] [Abstract][Full Text] [Related]
5. The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease.
Nitsch RM; Deng M; Tennis M; Schoenfeld D; Growdon JH
Ann Neurol; 2000 Dec; 48(6):913-8. PubMed ID: 11117548
[TBL] [Abstract][Full Text] [Related]
6. Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.
Parnetti L; Chiasserini D; Andreasson U; Ohlson M; Hüls C; Zetterberg H; Minthon L; Wallin AK; Andreasen N; Talesa VN; Blennow K
Acta Neurol Scand; 2011 Aug; 124(2):122-9. PubMed ID: 20880294
[TBL] [Abstract][Full Text] [Related]
7. Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease.
Nakamura T; Shoji M; Harigaya Y; Watanabe M; Hosoda K; Cheung TT; Shaffer LM; Golde TE; Younkin LH; Younkin SG
Ann Neurol; 1994 Dec; 36(6):903-11. PubMed ID: 7998778
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid of Alzheimer patients promotes beta-amyloid fibril formation in vitro.
Ono K; Noguchi M; Matsumoto Y; Yanase D; Iwasa K; Naiki H; Yamada M
Neurobiol Dis; 2005 Nov; 20(2):233-40. PubMed ID: 16242632
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides.
Bibl M; Esselmann H; Otto M; Lewczuk P; Cepek L; Rüther E; Kornhuber J; Wiltfang J
Electrophoresis; 2004 Sep; 25(17):2912-8. PubMed ID: 15349929
[TBL] [Abstract][Full Text] [Related]
11. Analysis of cerebrospinal fluid of Alzheimer patients. Biomarkers and toxic properties.
Marksteiner J; Pirchl M; Ullrich C; Oberbauer H; Blasko I; Lederer W; Hinterhuber H; Humpel C
Pharmacology; 2008; 82(3):214-20. PubMed ID: 18810245
[TBL] [Abstract][Full Text] [Related]
12. Increase in beta-amyloid levels in cerebrospinal fluid of children with Down syndrome.
Englund H; Annerén G; Gustafsson J; Wester U; Wiltfang J; Lannfelt L; Blennow K; Höglund K
Dement Geriatr Cogn Disord; 2007; 24(5):369-74. PubMed ID: 17914261
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid acetylcholinesterase activity in senile dementia of the Alzheimer type.
Tune L; Gucker S; Folstein M; Oshida L; Coyle JT
Ann Neurol; 1985 Jan; 17(1):46-8. PubMed ID: 3985585
[TBL] [Abstract][Full Text] [Related]
14. An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid.
Portelius E; Zetterberg H; Andreasson U; Brinkmalm G; Andreasen N; Wallin A; Westman-Brinkmalm A; Blennow K
Neurosci Lett; 2006 Dec; 409(3):215-9. PubMed ID: 17049739
[TBL] [Abstract][Full Text] [Related]
15. Changes in readthrough acetylcholinesterase expression modulate amyloid-beta pathology.
Berson A; Knobloch M; Hanan M; Diamant S; Sharoni M; Schuppli D; Geyer BC; Ravid R; Mor TS; Nitsch RM; Soreq H
Brain; 2008 Jan; 131(Pt 1):109-19. PubMed ID: 18056160
[TBL] [Abstract][Full Text] [Related]
16. Acetylcholinesterase activity in CSF in schizophrenia, depression, Alzheimer's disease and normals.
Deutsch SI; Mohs RC; Levy MI; Rothpearl AB; Stockton D; Horvath T; Coco A; Davis KL
Biol Psychiatry; 1983 Dec; 18(12):1363-73. PubMed ID: 6661467
[TBL] [Abstract][Full Text] [Related]
17. Release of acetylcholinesterase (AChE) from beta-amyloid plaques assemblies improves the spatial memory impairments in APP-transgenic mice.
Dinamarca MC; Arrázola M; Toledo E; Cerpa WF; Hancke J; Inestrosa NC
Chem Biol Interact; 2008 Sep; 175(1-3):142-9. PubMed ID: 18599028
[TBL] [Abstract][Full Text] [Related]
18. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease.
Hampel H; Shen Y
Scand J Clin Lab Invest; 2009; 69(1):8-12. PubMed ID: 18609117
[TBL] [Abstract][Full Text] [Related]
19. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
Gerhardsson L; Blennow K; Lundh T; Londos E; Minthon L
Dement Geriatr Cogn Disord; 2009; 28(1):88-94. PubMed ID: 19672066
[TBL] [Abstract][Full Text] [Related]
20. How well does the CSF inform upon pathology in the brain in Creutzfeldt-Jakob and Alzheimer's diseases?
Weller RO
J Pathol; 2001 May; 194(1):1-3. PubMed ID: 11329133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
